Our mission is to develop innovative solutions using 3D bioprinted human bone organoids to support early and effective treatment of bone diseases. Our primary focus is on bone metastases and osteosarcoma. Through the development of innovative research tools and diagnostics, we aim to improve drug development and provide healthcare providers with the insights necessary to make informed treatment decisions and early treatment adjustments. Our vision is to become the leading provider of organoid culture tools for bone diseases.
We are developing an advanced platform that produces mineralized and mechanically stimulated 3D bioprinted bone organoids from patient-derived cells to serve as a powerful research and diagnostic tool for bone diseases. With the aim of overcoming the limitations of traditional animal and 2D culture models, our platform will enable in vitro drug efficacy testing on human models that more closely replicate the relevant physiological conditions. Additionally, we aim to utilize this platform as an in vitro diagnostic tool to predict patient-specific disease prognosis and treatment response, offering significant potential for personalized medicine and clinical applications in the field of bone diseases.
We believe in the inherent uniqueness of every individual's life. This appreciation for individuality inspires our unwavering commitment to support researchers and healthcare providers in developing and selecting treatments that are specifically tailored to each patient's unique needs and circumstances.
Our culture is built on the principle that each individual has their own unique strengths that contribute to the greater whole. We empower each person to make decisions and take ownership of their responsibilities. Our actions are always guided by our vision, and we firmly believe that doing right by ourselves also means doing right by our customers.
We built a diverse core team with complimentary skillsets in biomechanical engineering, molecular biology, automation, clinical expertise and medtech business experience. Our technology platform is in development at ETH Zurich as a translational project. We are supported by a research grant from Personalized Health and Related Technologies, got early stage funding from Venturekick and benefit from the Initial Start-up Coaching by Innosuisse. At the sitem-insel school, we continue to develop our skills in translational medicine and biomedical entrepreneurship.
Let`s figure out how we can support each other on the way to our goals.
We are looking for partners, advisors, investors and clinical collaborators.
Just drop us a message. We would love to engage with you.